Si prevede che il mercato delle particelle simili a virus (VLP) raggiungerà i 7.858,82 milioni di dollari entro il 2028 rispetto ai 4.601,84 milioni di dollari del 2021; si prevede che crescerà a un CAGR del 7,9% dal 2021 al 2028.
La commercializzazione di vaccini a base di particelle virus-simili contro virus umani e animali, virus vigorosi le attività di ricerca e sviluppo per lo sviluppo di vaccini virali basati su particelle simili a virus e le particelle simili a virus che emergono come piattaforma immunoterapica affidabile per le malattie allergiche sono i principali fattori trainanti responsabili della crescita complessiva del mercato. Tuttavia, le sfide tecniche legate alla progettazione, purificazione e archiviazione degli eVLP ostacolano la crescita complessiva del mercato. Inoltre, le complessità associate alla produzione di vaccini con particelle simili a virus, insieme ai costi eccessivi e ai tempi richiesti dai processi (come la lavorazione a valle per vaccini a base di particelle simili a virus), limitano ulteriormente la crescita del mercato globale. Inoltre, le terapie basate su particelle simili a virus destinate alle malattie virali topiche ed emergenti, nonché al cancro, sono ancora in fase di sviluppo, il che offre opportunità redditizie per la crescita complessiva del mercato.
Approfondimenti strategici
È probabile che il Nord America continui a dominare il mercato delle particelle simili ai virus nel periodo dal 2021 al 2028. Gli Stati Uniti detengono la quota maggiore del mercato nordamericano e si prevede che questa tendenza continui durante il periodo di previsione. Ciò è principalmente attribuito alla suscettibilità comunemente osservata delle persone verso le infezioni virali, come l’influenza virale causata da diverse varianti. Inoltre, le continue attività di ricerca e sviluppo necessarie per la produzione di vaccini vivi attenuati costringono le aziende biofarmaceutiche a optare per particelle simili a virus, che supportano ulteriormente la crescita del mercato.
Regioni redditizie per il mercato delle particelle simili a virus (VLP)
Market Insights
I vaccini commercializzati basati su particelle simili a virus guidano la crescita complessiva del mercato
Secondo un rapporto pubblicato da Frontiers Media SA, il primo virus- Il vaccino a base di particelle simili è stato progettato per combattere un virus mortale, l’epatite B, e i vaccini a base di particelle simili a virus hanno prodotto risultati promettenti in termini di sicurezza rispetto ai vaccini tradizionali. Il primo vaccino commercializzato a base di particelle simili a virus è stato contro l’HBV. Inoltre, i vaccini commerciali anti-HBV, vale a dire "Engerix" prodotto da GlaxoSmithKline e "Recombivax HB" prodotto da Merck & Co. furono approvati nel 1980 ed erano tutte particelle simili a virus. Il successivo vaccino a base di particelle simili a virus disponibile in commercio è stato “Gardasil”, approvato nel 2006 per prevenire le infezioni da papillomavirus umano (HPV). Inoltre, le particelle simili ai virus vengono utilizzate anche in medicina veterinaria. Il primo vaccino veterinario disponibile in commercio basato su particelle virus-simili si è dimostrato efficace contro il circovirus suino di tipo 2 (PCV2).
Il ruolo delle particelle virus-simili nello sviluppo di prodotti immunoterapici contro le malattie allergiche stimola ulteriormente la crescita complessiva del mercato. particelle simili a virus sono utilizzate nel trattamento della rinite allergica, dell'asma e delle reazioni degli acari della polvere. I fattori sopra menzionati guidano la crescita del mercato complessivo delle particelle simili a virus in modo esponenziale. I vaccini con particelle simili a virus hanno mostrato una risposta immunitaria rapida con lievi reazioni cutanee come effetti collaterali.
Approfondimenti basati sul tipo di prodotto
In base al tipo di prodotto, il mercato delle particelle simili a virus è segmentato come epatite, cancro/HPV e Gaucher malattia. Il segmento dell’epatite rappresenterebbe un’ampia quota di mercato nel periodo 2021-2028. Il rapporto di Frontiers SA sottolinea che il virus dell’epatite C (HCV) infetta il 2% della popolazione mondiale ed è una delle principali cause di malattie epatiche e di trapianti di fegato. Questa minaccia medica può essere parzialmente affrontata con l’introduzione di nuove terapie antivirali. Ad esempio, un vaccino con un’efficacia del 50-80%, mirato ai consumatori di droghe per via endovenosa ad alto rischio, riduce drasticamente l’incidenza dell’HCV nella popolazione. Pertanto, le particelle simili a virus rappresentano una piattaforma di somministrazione di vaccini sicura e altamente immunogenica che induce una risposta immunitaria adattativa. Diversi vaccini basati su particelle simili a virus sono attualmente in fase di sperimentazione clinica; tuttavia, i vaccini VLP autorizzati per HBV e HPV sono in uso da molto tempo. Pertanto, i vaccini basati su particelle simili a virus hanno dimostrato la loro efficacia in relazione a caratteristiche immunologiche favorevoli e rendendoli uno dei vaccini più promettenti contro l'HCV.
Particelle simili a virus (VLP) Mercato, per tipo di prodotto: 2020 e 2028
Approfondimenti basati sulla fonte
In base alla fonte, il mercato delle particelle simili a virus (VLP) è segmentato in lievito, cellule di insetti, piante e altri. Il segmento del lievito detiene una quota di mercato considerevole e si prevede che continuerà la tendenza simile durante il periodo di previsione. le particelle simili a virus sono prodotte da sistemi di espressione eterologhi, che coinvolgono lieviti o baculovirus, nonché piante e batteri. La sicurezza dei vaccini a base di particelle virus-simili prodotti utilizzando sistemi di espressione di lievito contribuisce alla crescita del mercato delle particelle virus-simili a base di lievito.
Basato sull'applicazione Approfondimenti
Per applicazione, il mercato delle particelle simili a virus è segmentato in vaccini e terapie. Il segmento dei vaccini deterrà una quota considerevole del mercato nel 2021 ed è probabile che continui a dominare il mercato anche durante il periodo di previsione. La vaccinazione è considerata uno dei metodi più efficaci per controllare gli agenti patogeni e prevenire le malattie, sia nell’uomo che negli animali. I vaccini basati su particelle simili a virus rappresentano uno degli approcci più interessanti grazie alle loro proprietà immunogeniche intrinseche e alla loro sicurezza. Ad esempio, le particelle simili a virus sono antigeni multimerici non infettivi aventi una struttura particellare, adatti per l'induzione di una risposta immunitaria umorale e cellulare sicura ed efficiente. Oltre a ciò, i vaccini con particelle virus-simili hanno dimostrato la loro efficacia in campo veterinario. le particelle simili a virus sono composte solo da una o più proteine strutturali senza presenza di genomi di virus nativi e incapacità di autoreplicarsi nelle cellule. Tuttavia, particelle virus-simili contenenti antigene monovalente o multivalente possono essere prodotte in conformità con i requisiti di sorveglianza sierologica, l'utilità dei vaccini con particelle virus-simili si rivela promettente in campo veterinario. Uno di questi esempi di utilizzo di vaccini con particelle simili a virus nell'ambito delle strategie di vaccinazione DIVA (Differenziating Infected from Vaccined Animals) contro le malattie animali.
Aziende che operano nel settore delle particelle simili a virus ( VLP) adottano la strategia di innovazione del prodotto per soddisfare le richieste in continua evoluzione dei clienti in tutto il mondo, il che consente loro anche di mantenere il proprio marchio nel mercato globale.
Mercato delle particelle simili a virus (VLP) - per tipo di prodotto
- Epatite
- Cancro/HPV
- Malattia di Gaucher
Particelle simili a virus (VLP) ) Mercato - per fonte
- Lievito
- Cellula di insetto
- Pianta
- Altro
Virus -Mercato delle particelle simili (VLP): per applicazione
- Vaccini
- Terapeutici
Mercato delle particelle simili a virus (VLP): per area geografica
- Nord America
- Stati Uniti
- Canada
- Messico
< li>Europa - Francia
- Germania
- Italia
- Regno Unito
- Spagna
- Resto dell'Europa
- Asia Pacifico (APAC)
- Cina
- India
- Corea del Sud
- Giappone
- Australia
- Resto dell'area APAC
- Medio Oriente e Africa (MEA)
- Sud Africa
- Arabia Saudita
- Emirati Arabi Uniti
- Resto del MEA
- America centrale e meridionale (SCAM )
- Brasile
- Argentina
- Resto di SCAM
Profili aziendali
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global virus-like particles (VLP's) market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for virus-like particles (VLP’s). The US is estimated to hold the largest share in the virus-like particles (VLP’s) market during the forecast period. Presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for VLP’s accounting fastest growth of the region during the coming years.
Answer: - Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc., Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India Pvt. Ltd., BHARAT BIOTECH, LG Chem, and VBI Vaccines Inc. are among the leading companies operating in the global Virus-Like Particles (VLP's) market
The vaccine segment dominated the global virus-like particles (VLP's) market and accounted for the largest revenue of 4,558.08 Mn in 2021.
Based on product-type, hepatitis segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
American Society for Microbiology defines virus-like particles (VLP's) as non-infectious multiprotein structure that are engineered to self-assemble from viral structure proteins. VLP technology proves to be a very powerful tool involved in development of vaccines. Several VLP based vaccines exist in the global market involving hepatitis B virus and human papillomavirus.
Commercial VLP based vaccines against human and animal viruses, intensive research and development activities for the development of VLPs based vaccines effective against viral infections, and VLPs acting as the best immunotherapy platform for allergic diseases are the key driving factors responsible for the overall market growth.
The List of Companies - Virus-like Particles (VLP's) Market
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Nov 2021
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Nov 2021
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2021
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Nov 2021
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Nov 2021
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Nov 2021
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Nov 2021
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)